Methotrexate pneumonia lacking dyspnea and radiographic interstitial patterns during treatment for early rheumatoid arthritis: bronchoalveolar lavage and transbronchial lung biopsy in a differential diagnosis

References

• Suarez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P. Methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2000:CD000957.
   Google Scholar
• Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld FC, Dougados M, et al. Eular recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:34–45.
   PubMed Web of Science ®Google Scholar
• Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675–81.
   PubMed Web of Science ®Google Scholar
• Imokawa S, Colby TV, Leslie KO, Helmers RA. Methotrexate pneumonitis: review of the literature and histopathological fi ndings in nine patients. Eur Respir J 2000;15:373–81.
   PubMed Web of Science ®Google Scholar
• Grove ML, Hassell AB, Hay EM, Shadforth MF. Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice. QJM 2001;94:309–19.
   PubMedGoogle Scholar
• Zisman DA, McCune WJ, Tino G, Lynch JP, 3rd. Drug-induced pneumonitis: the role of methotrexate. Sarcoidosis Vasc Diffuse Lung Dis 2001;18: 243–52.
   Google Scholar
• Mori S, Imamura F, Kiyofuji C, Sugimoto M. Development of interstitial pneumonia in a rheumatoid arthritis patient treated with infl iximab, an anti-tumor necrosis factor alpha-neutralizing antibody. Mod Rheumatol 2006;16:251–5.
   PubMedGoogle Scholar
• Alarcon GS, Kremer JM, Macaluso M, Weinblatt ME, Cannon GW, Palmer WR, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, casecontrol study. Methotrexate-Lung Study Group. Ann Intern Med 1997;127:356–64.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Alarcon GS, Weinblatt ME, Kaymakcian MV, Macaluso M, Cannon GW, et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997;40:1829–37.
   PubMed Web of Science ®Google Scholar
• Ohosone Y, Okano Y, Kameda H, Fujii T, Hama N, Hirakata M, et al. Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis. J Rheumatol 1997;24:2299–303.
   PubMed Web of Science ®Google Scholar
• Searles G, McKendry RJ. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature. J Rheumatol 1987;14:1164–71.
   Google Scholar
• Prevoo ML, van �t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modifi ed disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.
   Google Scholar
• Lateef O, Shakoor N, Balk RA. Methotrexate pulmonary toxicity. Expert Opin Drug Saf 2005;4:723–30.
   PubMedGoogle Scholar
• Schnabel A, Richter C, Bauerfeind S, Gross WL. Bronchoalveolar lavage cell profi le in methotrexate induced pneumonitis. Thorax 1997;52:377–9.
   PubMed Web of Science ®Google Scholar
• White DA, Rankin JA, Stover DE, Gellene RA, Gupta S. Methotrexate pneumonitis. Bronchoalveolar lavage fi ndings suggest an immunologic disorder. Am Rev Respir Dis 1989;139:18–21.
   Google Scholar
• Cohen AJ, King TE Jr, Downey GP. Rapidly progressive bronchiolitis obliterans with organizing pneumonia. Am J Respir Crit Care Med 1994;149:1670–5.
   PubMed Web of Science ®Google Scholar
• Anaya JM, Diethelm L, Ortiz LA, Gutierrez M, Citera G, Welsh RA, et al. Pulmonary involvement in rheumatoid arthritis. Semin Arthritis Rheum 1995;24:242–54.
   PubMed Web of Science ®Google Scholar
• Rosenow EC 3rd, Myers JL, Swensen SJ, Pisani RJ. Drug-induced pulmonary disease. An update. Chest 1992;102:239–50.
   Google Scholar
• Nagai S, Aung H, Tanaka S, Satake N, Mio T, Kawatani A, et al. Bronchoalveolar lavage cell fi ndings in patients with BOOP and related diseases. Chest 1992;102:32S–7S.
   Google Scholar
• Carroll GJ, Thomas R, Phatouros CC, Atchison MH, Leslie AL, Cook NJ, et al. Incidence, prevalence and possible risk factors for pneumonitis in patients with rheumatoid arthritis receiving methotrexate. J Rheumatol 1994;21:51–4.
   PubMed Web of Science ®Google Scholar
• Furst DE, Koehnke R, Burmeister LF, Kohler J, Cargill I. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J Rheumatol 1989;16:313–20.
   Google Scholar
• Cooper GS, Blades EW, Remler BF, Salata RA, Bennert KW, Jacobs GH. Central nervous system Whipple's disease: relapse during therapy with trimethoprim-sulfamethoxazole and remission with cefi xime. Gastroenterology 1994;106:782–6.
   PubMedGoogle Scholar
• Sostman HD, Matthay RA, Putman CE, Smith GJ. Methotrexateinduced pneumonitis. Medicine (Baltimore) 1976;55:371–88.
   PubMed Web of Science ®Google Scholar
• Goldman GC, Moschella SL. Severe pneumonitis occurring during methotrexate therapy. Report of two cases. Arch Dermatol 1971;103:194–7.
   Google Scholar
• Goldblatt F, Isenberg DA. New therapies for rheumatoid arthritis. Clin Exp Immunol 2005;140:195–204.
   PubMed Web of Science ®Google Scholar